Pharming Group N.V. (PHGUF)
OTCMKTS · Delayed Price · Currency is USD
2.150
+0.300 (16.22%)
At close: Jan 27, 2026
Pharming Group Revenue
Pharming Group had revenue of $97.30M in the quarter ending September 30, 2025, with 30.00% growth. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue
297.20M
Revenue Growth
+21.15%
P/S Ratio
2.92
Revenue / Employee
896.72K
Employees
404
Market Cap
1.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.53M | 11.88% |
| Dec 31, 2019 | 189.64M | 34.36M | 22.12% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 2.41M | 163.98% |
| Dec 31, 2010 | 1.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
Pharming Group News
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PRNewsWire
- 8 days ago - Pharming Group: Crossing From Speculation To Profitability - Seeking Alpha
- 8 days ago - Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript - Seeking Alpha
- 10 days ago - FDA Strikes Off European Biotech Pharming's Immune Deficiency Drug For Expanded Use In Pediatric Patients - Benzinga
- 10 days ago - FDA Refuses To Approve Expanded Use Of Pharming's Joenja In Children With APDS - Nasdaq
- 10 days ago - Pharming Group (PHAR) Schedules Virtual Investor Day for February - GuruFocus
- 10 days ago - Pharming Group Receives FDA Complete Response Letter For Joenja Pediatric SNDA - Nasdaq
- 10 days ago - Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS - GlobeNewsWire